Genitourinary cancer Urachal cancer part 3

Proper management of urachal carcinoma surgical requires that the diagnosis was made preoperatively on the basis of recognition of this possibility in the appropriate clinical setting. Before read this part, please read Genitourinary cancer Urachal cancer part 2 . Cross-sectional images are the key to recognize the diagnosis. On CT, urachal carcinoma usually appears as a mass of low attenuation in the dome of the bladder, usually in the midline or slightly to one side. Due to the relatively high rate of recurrence after treatment of this disease, the resection of the umbilicus, urachus, covering the peritoneum and posterior rectus fascia lateral to the medial umbilical ligament, bladder, and lymph nodes of the pelvis is now normal. The recognition that urachal tumors are predominantly extravesical and is not associated with a defect in the camp suggested to surgeons that in most cases, even bulky tumors could be completely resected with adequate margins and en bloc dissection only a partial cystectomy. Contemporary series report that neither local recurrence nor result threatened by this approach. On the contrary, survival is rather linked to the stage of presentation, presence of metastases in lymph nodes, and the ability to achieve a negative surgical margin with the completion of a partial or total cystectomy. Radical cystectomy is indicated for salvage surgery to treat a positive surgical margin, or delete a ligament from inadequate control of urachus - which occurs when the diagnosis was made before the operation. In a series of patients referred to MD Anderson Cancer Center is remarkable that only 19 of 35 patients undergoing primary surgical treatment was resection of the urachal ligament and umbilicus. The importance of adequate surgical treatment was reinforced by the finding that 13 of the 16 long-term survivors referred to in this series were treated with en bloc resection including umbilectomy.

Unfortunately, patients with lymph node or peritoneal discovered in surgery have a median survival of about 25 months, and demonstrate a clinical course that is virtually indistinguishable from that of patients with clinically evident metastases at diagnosis. In view of this finding, and demonstrated benefit of perioperative chemotherapy for colorectal cancer, the use of adjuvant or neoadjuvant chemotherapy for urachal cancer appears to be a reasonable consideration. Unfortunately, there are essentially not affect the data on this point directly, so we were left to extrapolate from our experience with other intestinal adenocarcinomas. Since we have some systemic therapies with clinically relevant response rates (see below), it seems appropriate to discuss adjuvant therapy in patients at high risk of recurrence, even those with tumors in the lymph nodes or peritoneal surface, or in the environment of inadequate surgery, including the presence of positive margins and in the scenario where the urachal ligament was not controlled.

As expected, few long-term survivors were observed after developing metastases. The sites most frequently involved are the bones, lungs, liver, lymph nodes and brain. Peritoneal carcinomatosis is common, especially in the context of positive surgical margins and when the peritoneal implants are present in the cystectomy.

Historically, chemotherapy has had little impact on the treatment of urachal cancer. This is particularly true in the context of traditionally used chemotherapy regimens for TCC. More recently, the responses have been reported in the establishment of schemes of 5-fluorouracil-based chemotherapy. Today, they are enrolling patients in a Phase II trial of combination chemotherapy with 5-fluorouracil, leucovorin, gemcitabine and cisplatin. The results in the first 20 patients showed an objective response in just over a third of patients. According to the clinical manifestations of this disease is so closely related to colorectal cancer, anecdotal responses have been observed in patients treated with capecitabine and irinotecan-based regimens, and the antibody cetuximab antiepidermal growth factor.

Carcinoma is Uncommon Cancer Of The Bladder

Predominantly squamous cell carcinoma of the bladder is most commonly found in the environment of schistosomiasis in the Middle East, a context that is outside the scope of this chapter.

In the western, central squamous differentiation are commonly found in patients with invasive, non-papillary TCC. As is the case with focal glandular differentiation, we know you do not have clinical significance of this finding. By contrast, pure squamous cell carcinomas are rare, and show a very particular clinical expression. The most common scenario for (non-schistosomiasis) is that the chronic irritation squamous cell cancer, usually either urolithiasis (particularly staghorn calculi) or chronic catheters in patients with paraplegia and neurogenic bladder diseases such as MS. It is typical to see keratinizing squamous metaplasia, dysplasia often in areas adjacent to these cancers.

Surgery is the mainstay of therapy for squamous cell cancer. Local control is often a bigger problem than the progression from a distance, marked difference to the situation with conventional TCC. The sensitivity to chemotherapy is universally reported to be lower for the conventional squamous cell cancer of the CTP, which further reinforces the importance of primary surgical management. Unfortunately, when these cancers are recurrent or metastatic chemotherapy expectations are limited. However, there are certainly patients have excellent responses, and there is therefore difficult to assess the risk-benefit of a trial of chemotherapy. In our limited experience, we find the combination of gemcitabine (900mgm-2 for 90 minutes), cisplatin (50mgm-2), and ifosfamide (1000mgm-2) given every 14 days to be the most attractive pattern no a clinical trial.

Interestingly, lung metastases of carcinoma of the bladder tend to cavitation, the behavior is not typical of other histologies. Our experience in trying to administer chemotherapy in the special context of patients with paraplegia (or other diseases causing neurogenic bladder) is uniformly unsatisfactory, and we can not support the use of conventional treatments such as MVAC in this context.

Adenocarcinoma rare Cancers Of The Bladder

Glandular metaplasia is common in the urothelium, and the appearance of cystitis cystica and glandular cystitis are known consequences of chronic infection, inflammation or irritation (as urolithiasis). In the transformed state, focal areas of glandular differentiation are reasonably common in invasive non-papillary TCC. To our knowledge, focal areas of glandular differentiation have no clinical significance with regard to natural history or response to commonly used systemic agents. Moreover, it is rare to see a remnant of glandular differentiation in a piece of cystectomy after neoadjuvant chemotherapy for high grade, papillary TCC, even when nothing is seen adenocarcinomatous before therapy. These relatively common clinical scenarios highlight the morphological repertoire urothelial histology, and illustrate the difficulty of defining precisely what is meant by "adenocarcinoma of the bladder." In this section we limit our discussion to cancers that have adenocarcinoma histology as the dominant model, and recognizing the CTP.

There are many variants of adenocarcinoma found in the bladder. Most authors (including the World Health classification of tumors of the bladder) include mucinous ring, seal, type enteric hepatoid, and clear cell (formerly mesonephric) as recognizable subsets. In addition, an adenoid cystic pattern can also be seen, especially in the context of the transformation of a preexisting cystic cystitis. Tumors that mixtures of these patterns are the rule. Enteric type histology is particularly found among the cancers that originate in a urachal remnant, and these are taken separately in the "urachal cancer" below. However, villous adenoma and intestinal-type adenocarcinoma do occur rarely in the bladder properly. The immunophenotype of these cancers tend to overlap with that observed in colon cancer, and most produce carcinoembryonic antigen (CEA).

Most of the adenocarcinomas arising in the bladder are of the variety suitable mucinous or seal ring. The male / female ratio is at least 2: 1, and age of onset is very similar to that observed in conventional CTP. Bladder exstrophy, a rare developmental anomaly affecting 1 in 50 000 births, is a well-established risk factor, like other non-physiological states as a urinary bladder out of place. Intestinal metaplasia long before the appearance of carcinoma is typical in these contexts. Adenocarcinomas also arise in the context of preexisting cystic cystitis (and glandular), sometimes in association with schistosomiasis (although squamous histology is more common in the context of the latter).

It is typical to be diffusely infiltrative mucinous adenocarcinomas, and present with irritative symptoms out of proportion with the results of cystoscopy. Cross-sectional imaging typically shows diffuse thickening of the bladder walls, and plastic linitis Frank is well known, particularly in the subgroup with predominant signet ring histology. We have encountered patients not only with plastic linitis, but also with the involvement of seminal vesicles, and the extension, even to the spermatic cords. Thus, while the appearance may be mediocre cystoscopy, examination under general anesthesia, is striking.

The clear cell variant of adenocarcinoma of the bladder is very rare, and is also clinically distinct. These cancers often occur in women (at least 2: A female predominance) and the median age is younger. More than half of the cases appear to arise from the urethra or periurethral glands. Usually express CA125, and there are other lines of evidence supporting an etiology of M ullerian rest.

These cancers tend to be very sensitive to taxane-based therapy, such as those used for epithelial ovarian cancer. The optimal clinical management of adenocarcinoma is, of course, are not established. The stadium is the most important prognostic factor, and unfortunately the majority of patients with adenocarcinoma presented with locally advanced disease (cT3 or higher).

Therefore, for many patients, neoadjuvant systemic therapy is a reasonable consideration as historical results for surgery alone in this environment is poor. Most patients in our center are, in fact, treated with combination chemotherapy followed by radical surgery. We have seen the answers to a variety of chemotherapy regimens.

In the metastatic setting, we find many examples of patients who had an excellent response to chemotherapy, including the standard therapy for TCC. However, the overall response rate is lower than seen with conventional TCC, and the survival of more than 2 years is uncommon

Rare cancers of the bladder

Found rare tumors that arise in the bladder fall naturally into two groups: rare histologies and tumor urothelial origin nonurothelial. Our discussion follows these lines, and took the unusual urothelial cancer in the first place, since these are by far the most common and clinically important. Most of what is called transitional cell carcinoma, about 80%, in fact, low histological grade and reflects mainly hyperplastic process. This process typically results in the papillary architecture of the mass thickness of cell proliferation, but not invasive. These injuries, known as "Ta", tend to recur and may progress to dysplasia and invasion in 15 to 20% of patients. However, for the most part, these tumors are more similar to polyps’ true carcinomas. An averlapping but definite pattern can be recognized in the remaining 20% of cases. In this group, high histological grade dysplasia and invasion are hallmarks.

These "non-papillary" cancers are the cause of most mortality, and show a significant range of histomorphology. In the end, they are so different from transitional cell carcinoma (TCC) that called for an alternative taxonomy. Although very rare as "pure" variant, the fact remains that about one third of non-papillary bladder cancers exhibit at least focal areas of unusual histologies discussed below. Therefore, in practice, there is considerable uncertainty about which of the cases showing lesser degrees of histological variant is considered really outside the normal spectrum of TCC, and should be classified as distinct entities.